The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organisation (CDSCO), has granted ...

Eli Lilly announces positive results from phase 3 ACHIEVE-2 & ACHIEVE-5 trials of orforglipron versus dapagliflozin in adults with type 2 diabetes: Indianapolis Thursday, October ...

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all these options stack up. Are there benefits … ...

Orforglipron, a novel oral GLP-1, was superior to dapagliflozin for reducing HbA1c in adults with type 2 diabetes ...

Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its ...

In a major development for diabetes care in India, Dr. Reddy's Labs has got the go-ahead from the Subject Expert Committee ...

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint In ACHIEVE-5, orforglipron lowered A1C by ...

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data ...

Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...

The proportion of participants achieving HbA1c < 7.0% and a =10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide ...

Eli Lilly (LLY) stock is in focus as the company's oral weight loss candidate orforglipron succeeds in two Phase 3 trials for ...

Semaglutide (Ozempic), a once-weekly injectable already approved globally, has now been cleared for use in India for type 2 ...